Probi probiotics reduce gut problems in connection with cancer radiotherapy
PRESS RELEASE
A randomized, double-blind, placebo-controlled trial with Probi’s two probiotic strains, HEAL9TM and LP6595, was shown to reduce gastrointestinal problems for women receiving pelvic radiotherapy.
The 3-armed study included 75 women with gynecological cancer receiving pelvic radiotherapy. The patients were either given a high or a low dose of the combined probiotic strains HEAL9TM and LP6595 or placebo and was conducted on two sites in Sweden.
“When receiving radiotherapy in connection with gynecological cancer, women often experience gastrointestinal problems during